Banner
WHAT'S NEW
MEDIA
2024-10-07
AMS BioteQ Showcases Innovative Medical Products at Medical Japan in Tokyo

 

Medical Japan 2024 Tokyo, a premier healthcare exhibition encompassing medical care, elderly care, diagnostics, and drug development, is set to commence on Oct. 9th at Makuhari Messe, Chiba. AMS BioteQ, a Taiwanese biotech startup, will make its return appearance, showcasing groundbreaking medical innovations that have already garnered significant attention prior to the exhibition.

 

 

Innovative Medical Solutions

The company's flagship product, “SIPSIP Foam” dressing, has successfully obtained Class I medical device registration approval from Japan's PMDA (Pharmaceuticals and Medical Devices Agency). This year, AMS BioteQ will present its expanded SIPSIP series of innovative medical devices and pharmaceutical research achievements.

 

 

Advanced Wound Care Solutions

The SIPSIP innovative medical series remains a focal point of this year's exhibition. Building upon the success of SIPSIP Foam dressing, which has already secured Japanese medical device approval, AMS BioteQ introduces SIPSIP Pro hydrogel dressing, designed specifically for deep wound care needs. This new product, with its unique material composition and design, promises superior wound care performance, anticipated to create significant market impact in Japan.

 

 

Clinical Breakthroughs: Premium Vitality Drink "Chi"

AMS BioteQ presents a specialized formulation drink, Premium Vitality Drink "Chi," developed for post-operative cancer patient care. The product has successfully completed clinical trials at E-Da Hospital, demonstrating significant improvements in patients' post-operative quality of life. Dr. SU, Yu-Chieh, Chief of Hematology-Oncology at E-Da Hospital, Taiwan, will be present to discuss the clinical trial outcomes and the drink's potential in alleviating chemotherapy and radiotherapy side effects.

 

 

Antiviral Drug Development

AMS-2140, a promising antiviral drug development project, represents another significant research milestone. This drug compound demonstrates effectiveness against various emerging viruses, including dengue fever and avian influenza. AMS BioteQ seeks potential collaboration partners for further drug development at this exhibition.

 

 

    AMS BioteQ welcomes healthcare professionals and industry specialists to explore their latest innovations. Their expert team will be available on-site to provide detailed product information and discuss potential collaborations.

 

    The company looks forward to showcasing their achievements in the Japanese market and facilitating meaningful discussions about the future of healthcare innovation.